Phase 1 Study of Pritumumab in Brain Cancer - Nascent Biotech

By Nascent Biotech

Posted December 6, 2023

In

Phase 1 Study of Pritumumab in Brain Cancer

Recent Posts

VIDEO: Nascent Biotech CEO Sean Carrick at the Emerging Grown Conference
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued